AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases

Sep 30, 2020•almost 5 years ago

Amount Raised

$70 Million

Round Type

series a

San FranciscoAgriculture And FarmingBiotechnologyScience And EngineeringHealth Care

Description

Sonoma Biotherapeutics, a privately held company developing regulatory T-cell (Treg) therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million. Investors participating in the round include Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund and additional undisclosed investors.

Company Information

Company

Sonoma Biotherapeutics

Location

San Francisco, California, United States

About

Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech